AnaptysBio (ANAB) Given a $143.00 Price Target at Credit Suisse Group

Credit Suisse Group set a $143.00 target price on AnaptysBio (NASDAQ:ANAB) in a report issued on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also issued reports on ANAB. Cantor Fitzgerald set a $124.00 price target on AnaptysBio and gave the stock a buy rating in a report on Saturday, September 22nd. Wedbush reissued an outperform rating and set a $138.00 price target on shares of AnaptysBio in a report on Tuesday, September 18th. Zacks Investment Research lowered AnaptysBio from a buy rating to a hold rating in a report on Tuesday, October 9th. Stifel Nicolaus set a $127.00 price target on AnaptysBio and gave the stock a buy rating in a report on Friday, September 14th. Finally, JMP Securities lowered their price target on AnaptysBio from $180.00 to $153.00 and set a buy rating on the stock in a report on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $130.50.

Shares of NASDAQ ANAB traded down $8.71 during midday trading on Friday, reaching $72.33. 836,519 shares of the company were exchanged, compared to its average volume of 312,129. The company has a quick ratio of 16.19, a current ratio of 16.19 and a debt-to-equity ratio of 0.01. AnaptysBio has a 1 year low of $65.93 and a 1 year high of $134.00. The firm has a market cap of $2.07 billion, a P/E ratio of -47.59 and a beta of 3.47.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.05. The company had revenue of $5.00 million for the quarter. As a group, analysts anticipate that AnaptysBio will post -2.72 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC boosted its holdings in AnaptysBio by 11.7% in the 3rd quarter. FMR LLC now owns 3,935,467 shares of the biotechnology company’s stock valued at $392,642,000 after purchasing an additional 410,918 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in AnaptysBio by 11.1% in the 3rd quarter. Janus Henderson Group PLC now owns 3,143,155 shares of the biotechnology company’s stock valued at $313,592,000 after purchasing an additional 312,833 shares in the last quarter. BlackRock Inc. boosted its holdings in AnaptysBio by 11.1% in the 3rd quarter. BlackRock Inc. now owns 1,627,140 shares of the biotechnology company’s stock valued at $162,341,000 after purchasing an additional 162,516 shares in the last quarter. OppenheimerFunds Inc. boosted its holdings in AnaptysBio by 5.2% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,101,887 shares of the biotechnology company’s stock valued at $78,278,000 after purchasing an additional 54,773 shares in the last quarter. Finally, Federated Investors Inc. PA boosted its holdings in AnaptysBio by 11.4% in the 2nd quarter. Federated Investors Inc. PA now owns 491,400 shares of the biotechnology company’s stock valued at $34,909,000 after purchasing an additional 50,170 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Recommended Story: Capital gains and your 401(k) or IRA

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply